分析证实，两组类器官均发育出具有气道和肺泡特征的肺样结构。RNA测序显示，它们形成了具 有典型特征的上皮细胞与中胚层肺细胞。 尽管两组类器官发育出的细胞类型相同，但比例略有差异。例如，人工培养的类器官含有更多肺泡 细胞，而生物反应器中的类器官体积较大，肺泡球结构较少。 生物反应器可一次性量产类器官，显著减轻了人工负担，有望改变肺病研究格局。未来患者或可利 用自身组织，通过该反应器培育个性化类器官，提前测试治疗方案的有效性。 团队首先选取干细胞，令其在培养皿中增殖。待细胞充分生长后，将其分离并"激活"，形成小型细 胞聚集体，即胚状体。随后，他们将胚状体置于特殊生物反应器中，其中含有促进类器官生长的培养 液。同时，团队还人工培养了一组类器官作为对照。 这些结构在反应器中生长4周后，团队通过显微镜、免疫荧光、免疫组化及RNA测序进行分析，以 了解类器官的发育过程、细胞类型及其与传统培养类器官的差异。 科技日报讯 （记者刘霞）德国杜伊斯堡-埃森大学科学家在近日出版的《生物工程与生物技术前 沿》杂志发表论文称，他们开发出一种自动化制备方法，可批量生产微型肺类器官。这种类器官包含真 实肺细胞微结构，能更有效地测试实验药物 ...

Core Insights - The upcoming "15th Five-Year Plan" emphasizes the construction of a modern industrial system and the strengthening of the real economy as a strategic priority, focusing on the development of emerging and future industries [1][2] Emerging Industries - The plan aims to cultivate new pillar industries, accelerating the development of strategic emerging industry clusters such as new energy, new materials, aerospace, and low-altitude economy, potentially creating several trillion-yuan markets [2] - Future industries like quantum technology, biomanufacturing, hydrogen energy, nuclear fusion, brain-computer interfaces, and sixth-generation mobile communication are highlighted as new economic growth points [2][4] City-Level Developments - Cities like Beijing, Shanghai, and Shenzhen continue to lead in emerging industries, while newer cities like Hangzhou and Hefei are also making significant strides [3] - Hefei is recognized as a hub for quantum technology, housing nearly one-third of the country's quantum enterprises and establishing a complete ecosystem from research to industrialization [7] Quantum Technology - Hefei's quantum technology sector is experiencing a financing boom, with companies like Benyuan Quantum and Guo'an Quantum preparing for IPOs, indicating strong market interest [7] - The city is implementing a "technology innovation + scenario application" initiative, allocating at least 30 million yuan to develop urban and industrial scenarios [7] Biomanufacturing - The biomanufacturing industry in China is nearing a total scale of 1 trillion yuan, with competitive clusters emerging in cities like Shanghai, Beijing, and Shenzhen [9][10] - Shenzhen is becoming a highland for synthetic biology, with 40% of new synthetic biology enterprises established there in the past three years [10] Hydrogen and Nuclear Fusion - Hydrogen energy and nuclear fusion are identified as key future industries, with over 20 provinces outlining long-term plans for hydrogen energy development [14] - Chengdu and Hefei are leading in nuclear fusion research, with significant advancements in experimental conditions for fusion energy [15] Brain-Computer Interfaces - The brain-computer interface market is projected to reach approximately $2.62 billion by 2024, with cities like Beijing, Shanghai, Shenzhen, and Hangzhou taking the lead in developing this technology [16][20] - Policies are being implemented to foster a competitive ecosystem in brain-computer interfaces, aiming to cultivate globally influential enterprises by 2030 [19] Embodied Intelligence - The embodied intelligence market in China reached 418.6 billion yuan in 2023, with expectations for growth driven by advancements in AI technology [21][22] - Cities are competing to establish themselves as leaders in this sector, with Beijing and Shenzhen targeting the development of a trillion-yuan industry cluster by 2027 [22][23] Sixth-Generation Mobile Communication - Nanjing is emerging as a key player in the 6G sector, having established a comprehensive experimental platform and hosting significant industry events [26][27] - Traditional communication strongholds like Beijing and Shanghai continue to maintain their advantages while developing supportive policies for 6G applications [26][27]

Core Viewpoint - The company has terminated the planned acquisition of 55% of Shanghai CanShine Engineering Equipment Co., Ltd., which has drawn market attention, but this decision will not adversely affect its business operations or financial status [1][2]. Group 1: Acquisition Details - The acquisition was aimed at addressing core pain points in the biopharmaceutical sector and enhancing the company's strategic layout in this area [2]. - Shanghai CanShine possesses core capabilities in high-end biopharmaceuticals, including monoclonal antibodies and vaccines, which align well with the company's existing business [2]. - The termination of the acquisition was due to the inability to reach consensus on key terms, reflecting the company's commitment to shareholder interests and prudent decision-making [2][3]. Group 2: Strategic Focus - The company remains committed to its strategic focus in the semiconductor and biopharmaceutical sectors, emphasizing its modular overall solutions that meet overseas biopharmaceutical clients' needs for efficient delivery and compliance [3]. - Continuous investment in independent innovation has led to the establishment of a modular manufacturing base, supporting scalable and standardized development [3]. - The company plans to leverage favorable policies and market conditions to enhance its integrated solutions in biopharmaceutical cleanroom systems and core process systems, aiming to meet evolving customer demands and improve competitive strength [3].

Core Viewpoint - The article highlights high-paying job opportunities in the laboratory instrument sales sector, emphasizing the demand for skilled professionals in various roles across different cities in China [2][3][5][10]. Job Opportunities - Positions available include Laboratory General Instrument Sales Engineer in Guangzhou with a salary range of 8k-15k, requiring a background in chemistry, pharmacy, or related fields [2]. - Sales Project Manager in Shanghai offers a salary of 10k-20k, requiring a degree in chemistry or biology and at least three years of sales experience in the instrument industry [3][4]. - CRO Industry Development Manager in Beijing with a salary range of 15k-30k, requiring familiarity with CRO operations and experience in chromatography instruments [5]. - Application Engineer for Bioreactors in Suzhou, offering 10k-20k, focusing on customer technical support and product improvement [8]. - Sales Engineer positions available at various companies, including Agilent and Anton Paar, with salaries ranging from 18k-28k and requiring relevant industry experience [10][13]. Candidate Requirements - Most positions require a bachelor's degree or higher in relevant fields such as chemistry, biology, or materials science [4][14]. - Candidates should possess strong sales experience, communication skills, and the ability to work independently [4][11]. - Specific technical knowledge related to laboratory instruments and experience in customer engagement are emphasized across various roles [5][8][14].

Group 1 - The second academic conference on bioreactor engineering and biomanufacturing was held in Shanghai, focusing on cutting-edge technologies and industry development in the field [1] - East China University of Science and Technology aims to seize opportunities in the biomanufacturing sector, enhancing research in fine chemicals, electronic chemicals, and new energy [1] - Advanced biomanufacturing is recognized as a disruptive technology that transcends traditional disciplines, necessitating a new foundational development logic [1][2] Group 2 - Bioreactors are identified as the "core engine" of biomanufacturing, with next-generation intelligent bioreactors expected to facilitate the efficient conversion of synthetic biology achievements [1] - The importance of bioreactor engineering in the industrialization of synthetic biology outcomes is emphasized, calling for enhanced collaboration between industry, academia, and research [1] - Key figures in the field discussed various topics, including the development of synthetic biology, the application of core materials in biopharmaceutical innovation, and the upgrade of the health industry driven by food and medicine integration [2]

Core Viewpoint - Shanghai Aopumai Biotechnology Co., Ltd. plans to acquire 100% equity of Pengli Biotechnology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, involving multiple investment partners [1][3]. Group 1: Acquisition Details - The acquisition involves multiple investment entities, including PharmaLegacy Hong Kong Limited and several limited partnerships, indicating a broad consortium of investors [1]. - The company intends to raise supporting funds by issuing shares to no more than 35 specific investors as part of this transaction [3]. Group 2: Regulatory Compliance - The transaction is in accordance with the "Major Asset Restructuring Management Measures" which stipulates that continuous purchases or sales of the same or related assets within twelve months must be cumulatively calculated [3][4]. - The assets involved in the transaction are recognized as belonging to the same or similar business scope, thus requiring inclusion in the cumulative calculation for this transaction [5]. Group 3: Financial Adjustments - The company has adjusted its capital increase plan for its subsidiary, increasing the planned investment from 20 million RMB to 5 million RMB, reflecting a strategic shift in resource allocation [4]. - The company has also made additional investments in other subsidiaries, such as a 42 million RMB increase in Suzhou Haixing Biotechnology Co., Ltd., acquiring a 30.0014% stake [4][5].